GTC
IMVT icon

Ghost Tree Capital’s Immunovant IMVT Stock Holding History

Ghost Tree Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,000
Closed -$3.26M – 61
2023
Q3 		$3.26M Buy
+85,000
New +$1.92M 1.07% 33

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Ghost Tree Capital's IMVT Position: Q3 2024 in Review

Ghost Tree Capital reduced its Immunovant (IMVT) stake by 17% in Q3 2024, selling an estimated $1.33M and leaving 215,000 shares worth $6.13M. The position accounts for 1.85% of the portfolio, ranked #23.

Ghost Tree Capital first reported a position in IMVT in Q4 2019 and has held it in 10 quarters since. The position peaked at $18.5M in Q3 2020. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Ghost Tree Capital held 215,000 shares of Immunovant worth $6.13M as of Q3 2024.
  • Ghost Tree Capital sold 45,000 Immunovant shares in Q3 2024, an estimated $1.33M.
  • Immunovant made up 1.85% of Ghost Tree Capital's portfolio in Q3 2024, its #23 holding.
  • Ghost Tree Capital first reported a position in Immunovant in Q4 2019 and has held it in 10 quarters since.
  • Ghost Tree Capital's Immunovant position peaked at $18.5M in Q3 2020.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.